The use of models is a key feature of preclinical studies and in recent months there have been several new advancements in this area. This article investigates five of the latest developments.
List view / Grid view
Filter the results
From the world’s flagship neutron science facility, Institut Laue-Langevin (ILL), Matthew Blakeley shares insights into how they are harnessing the power of neutrons to aid their search for new cancer treatments.
Charlotte Walker-Osborn, a Partner and Head of Technology Sector (International) at global law-firm Eversheds Sutherland and a legal expert in technology law, explains some of the challenges and potential future of artificial intelligence (AI) in the field of drug discovery.
The potential of three-dimensional cell culture models is now well-recognised by scientists; however, there are still some challenges. Margaritha Mysior and Jeremy Simpson address some of the common challenges of working with spheroids and organoid models – including how they are developed and how to obtain high-resolution, high-content images and…
This article outlines the exciting developments that are taking place with immunotherapies and demonstrates how stem-cell technologies are proliferating the paradigm shift in how we tackle cancer treatment.
Thanks to new developments with induced pluripotent stem cells enabling generation of human neurons, scientists can more precisely analyse the effects that chemicals have on human cells. This article describes research into the effects of cannabis on neuronal development and implications of its legalisation in Canada.
Scientists from LifeArc, an independent medical research charity in the UK, explain how they’re using the latest imaging technologies to progress drug discovery campaigns and identify the most promising candidates for antibody-based therapies.
Native mass spectrometry has the potential to be a fast, simple, highly sensitive and automatable technique for compound screening in drug design and discovery. In this article, Rod Chalk and Nicola Burgess-Brown discuss the key attributes of native mass spectrometry and reasons why it is not yet widely employed.
Progressing drug discovery projects to a stage that attracts commercial interest is a challenging endeavour, evidenced by the fact that only a small proportion of drug discovery projects are successfully progressed to such a stage. A major cause of this is the lack of comprehensive profiling of compounds prior to…
For the past thirty years, native mass spectrometry has grown in both scope and reach in labs across the globe to encompass larger and more challenging molecular complexes. However, up until now, the throughput of these techniques has been slow and manual. Christopher Nortcliffe discusses ways that native analysis is…
Conventional methods for radiolabelling proteins are time consuming and difficult to automate. In this article, Jason P. Holland discusses how combining photochemistry with radiochemistry enables development of radiolabelled proteins far more quickly and easily – literally in a flash of light.
The advent of CRISPR/Cas9 gene editing, together with the plummeting cost of whole-genome sequencing, has cleared a path for the development of customised cancer cell models. Here, we discuss recent developments in the field and challenges associated with targeted-therapy resistance.
High-content screening (HCS) approaches have become increasingly common in drug discovery with HCS technologies integrated across the drug discovery pipeline. Here we discuss recent developments in this arena.
This in-depth focus discusses screening and the uses of phenotypic profiling in drug discovery. Also examined is the role that CRISPR/Cas9 gene editing and native mass spectrometry play.
In this in-depth focus, the challenges of imaging are explored including how to develop high-resolution images. Also discussed are new imaging technologies to aid drug discovery.